Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Dormitzer also took the lead on Pfizer's respiratory syncytial virus (RSV) vaccine candidates ... now started testing, while GSK has also focused on providing its adjuvant technology to other ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

The CDC reported the mistake involving two vaccines used to treat RSV, a serious respiratory ... Neither of the vaccines, ...

These findings have been implemented by GSK and Pfizer to utilize the pre-F RSV protein as their immunogen for vaccine research. The availability of high purity, conformationally verified proteins ...

“Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine, show potential to ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...